Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients

Table 2 Correlation between fibrinogen concentration and clinicopathological characteristics in gallbladder cancer patients n (%)

Characteristics	Fibrinogen concentration		P value
	≤ 3.47 g/L (n = 75)	> 3.47 g/L (n = 79)
Age (yr)
≤ 60	31 (20.1)	25 (16.2)	0.243
> 60	44 (28.6)	54 (35.1)
Sex
Male	33 (21.4)	30 (19.5)	0.513
Female	42 (27.3)	49 (31.8)
Cholecystolithiasis
Absent	38 (24.7)	41 (26.6)	0.878
Present	37 (24.0)	38 (24.7)
Diabetes
Absent	57 (37.0)	59 (38.3)	0.850
Present	18 (11.7)	20 (13.0)
Jaundice
Absent	68 (44.2)	61 (39.6)	0.029
Present	7 (4.5)	18 (11.7)
Blood groups
A	19 (12.3)	24 (15.6)	0.145
B	33 (21.4)	23 (14.9)
AB	2 (1.3)	7 (4.5)
O	21 (13.6)	25 (16.2)
Pathological types
Adenosquamous carcinoma	0 (0)	3 (1.9)	0.142
Adenocarcinoma	75 (48.7)	75 (48.7)
Papillocarcinoma	0 (0)	1 (0.6)
Degree of differentiation
Poor	23 (14.9)	37 (24.0)	0.048
Moderate-well	52 (33.8)	42 (27.3)
Resection margin status
Negative	56 (36.4)	40 (26.4)	0.003
Positive	19 (12.3)	39 (25.3)
Maximum tumor diameter (cm)
≤ 2.45	34 (22.1)	34 (22.1)	0.871
> 2.45	41 (26.6)	45 (29.2)
T stage
Tis-T1a	8 (5.2)	2 (1.3)	< 0.001
T1b-T2b	22 (14.3)	7 (4.5)
T3	43 (27.9)	60 (39.0)
T4	2 (1.3)	10 (6.5)
N stage
N0	50 (32.5)	48 (31.2)	0.748
N1	21 (13.6)	26 (16.9)
N2	4 (2.6)	5 (3.2)
Distant metastasis
Absent	69 (44.8)	73 (47.4)	0.925
Present	6 (3.9)	6 (3.9)
TNM stage
0-Istage	12 (7.8)	4 (2.6)	0.011
IIA-IIB stage	12 (7.8)	4 (2.6)
IIIA-IIIB stage	39 (25.3)	53 (34.4)
IVA-IVB stage	12 (7.8)	18 (11.7)
CA199 (U/mL)
≤ 39	41 (26.6)	25 (16.2)	0.005
> 39	34 (22.1)	54 (35.1)
Albumin levels (g/L)
≤ 40.5	32 (20.8)	44 (28.6)	0.111
> 40.5	43 (27.9)	35 (22.7)
FAR
≤ 0.08	59 (38.3)	12 (7.8)	< 0.001
> 0.08	16 (10.4)	67 (43.5)

FAR: Fibrinogen to albumin ratio.